Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilima...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

Biotechguy21 Jul. 14 at 8:34 PM

$AGEN same ceo of 30 years. now he is cfo and his son is a big part of the game. Jenny does the same atm games at $INKT and both companies are failing shs week by week. epic money machine 😂😂😂😂

0 · Reply

Dancady1 Jul. 13 at 10:15 PM

$INKT nom num nom

0 · Reply

Biotechguy21 Jul. 13 at 7:09 PM

$AGEN $INKT remember how fast these pos companies atm a sp to death. Facts and stay tuned 🤡😂🤡😂🤡

0 · Reply

Spartrap Jul. 13 at 2:39 PM

$INKT AGEN's major runway extension will more than probably benefit INKT. Also nice to see those guys that work for both companies know how to setup a deal and execute. I plan to buy more in the coming months before ARDS results

1 · Reply

pedmac2000 Jul. 10 at 1:49 PM

$AGEN $INKT $IBRX Probably good to keep an eye on INKT. I think ImmunityBio’s pneumonia/sepsis Trial is combo’d with INKT’s. 30 Patients, complete by Nov 2026. Was Giuliani in Trial? Trump’s statement about a friend who was given Last Rites with family crying, and then a few days later was out of the hospital?

1 · Reply

svertical1 Jul. 10 at 7:41 AM

$INKT $IBRX Probably good to keep an eye on INKT. I think ImmunityBio’s pneumonia/sepsis Trial is combo’d with INKT’s. 30 Patients, complete by Nov 2026. Was Giuliani in Trial? Trump’s statement about a friend who was given Last Rites with family crying, and then a few days later was out of the hospital?

1 · Reply

weichsel1 Jul. 9 at 1:51 PM

$INKT "Preliminary data are expected in the second half of 2026" - The C-1300-02 trial is a randomized Phase 2 study evaluating agenT-797 plus standard of care compared with placebo plus standard of care in adults with acute lung injury and critical illness, including moderate to severe acute hypoxemic respiratory failure. https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-announces-first-patient-dosed-randomized-phase

0 · Reply

Dancady1 Jul. 7 at 1:40 PM

$INKT no news for a while now…. Maybe some positive news with the patient in Ukraine being dosed a month ago

0 · Reply

OrientBeach Jul. 4 at 5:24 PM

$INKT Just to make a correction. Everglade is a solicitation agent for BARDA and NOT the name of BARDA’s ARDS program

0 · Reply

OrientBeach Jul. 3 at 4:00 PM

$INKT It would certainly appears as if Mink’s Agent-797 has been enrolled into BARDA’s Everglades ARDS program. The Responses Deadline was April 15th and Mink’s Lviv trial started May 14th. I have been following the candidates since ‘23 when the ARDS program was once called DRIVe. Rigel’s Fostamatinib drug is also a candidate, and their trial is scheduled to start in August. Rigel received $750.0K in funds to further study Fostamatinib back in Sept ‘23. I am not a scientist so I am unable to speculate on which drug is better https://everglade.com/barda-rfi-on-host-directed-therapeutics-for-ards-prevention/

3 · Reply

MiNK Therapeutics Transcript: AGM 2026

Jun 3, 2026, 4:30 PM EDT - 5 weeks ago

MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting

2026-05-28T14:12:03.000Z - 6 weeks ago

MiNK Therapeutics doses first patient in agenT-797 trial

May 28, 2026, 9:04 AM EDT - 6 weeks ago

MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

2026-05-20T15:15:48.000Z - 7 weeks ago

MiNK Therapeutics reports new data on agenT-797 at ATS 2026

May 20, 2026, 11:07 AM EDT - 7 weeks ago

MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications

May 15, 2026, 8:30 AM EDT - 2 months ago

MiNK Therapeutics Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 2 months ago

MiNK Therapeutics Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 2 months ago

MiNK Therapeutics Quarterly report: Q1 2026

May 15, 2026, 7:30 AM EDT - 2 months ago

MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation

IBRX

2026-05-14T17:31:11.000Z - 2 months ago

MiNK Therapeutics initiates agenT-797 clinical trial

May 14, 2026, 7:30 AM EDT - 2 months ago

MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness

May 12, 2026, 7:35 AM EDT - 2 months ago

MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026

May 8, 2026, 4:30 PM EDT - 2 months ago

MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

Apr 30, 2026, 8:00 AM EDT - 2 months ago

MiNK Therapeutics Proxy statement: Proxy filing

2026-04-20T17:05:20.000Z - 3 months ago

MiNK Therapeutics management to meet virtually with B. Riley

$MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026$

Apr 3, 2026, 7:30 AM EDT - 3 months ago

MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Apr 1, 2026, 7:30 AM EDT - 3 months ago

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

Mar 31, 2026, 8:30 AM EDT - 3 months ago

MiNK Therapeutics Earnings Call Transcript: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 3 months ago

MiNK Therapeutics Annual report: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 3 months ago

MiNK Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 7:30 AM EDT - 3 months ago

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Mar 17, 2026, 7:30 AM EDT - 4 months ago

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

2026-03-11T14:11:00.000Z - 4 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC LGVN

2026-03-10T12:33:59.000Z - 4 months ago

Why Is MiNK Therapeutics Stock (INKT) Up Today?

2026-03-10T09:40:45.000Z - 4 months ago

MiNK Therapeutics announces strategic collaboration with C-Further

Mar 10, 2026, 5:30 AM EDT - 4 months ago

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

2026-02-04T10:25:19.000Z - 5 months ago

MiNK Therapeutics announces new invariant natural killer T cells data

Feb 3, 2026, 9:30 PM EST - 5 months ago

MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

2026-01-08T17:10:24.000Z - 6 months ago

MiNK, University of Wisconsin-Madison announce Phase 1 agenT-797 trial

Jan 8, 2026, 12:00 PM EST - 6 months ago

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Dec 10, 2025, 7:00 AM EST - 7 months ago

MiNK Therapeutics Registration statement: Registration Filing

2025-11-20T16:45:18.000Z - 8 months ago

MiNK Therapeutics announces publication of new preclinical data for MiNK-215

Nov 20, 2025, 11:42 AM EST - 8 months ago

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

Nov 14, 2025, 8:30 AM EST - 8 months ago

MiNK Therapeutics Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:30 AM EST - 8 months ago

MiNK Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 8 months ago

MiNK Therapeutics Earnings release: Q3 2025

2025-11-14T12:35:56.000Z - 8 months ago

MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year

2025-11-07T22:00:18.000Z - 8 months ago

MiNK Therapeutics files $150M mixed securities shelf

2025-11-07T14:05:54.000Z - 8 months ago

MiNK Therapeutics reports updated clinical results on agenT-797

$MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025$

Nov 7, 2025, 9:00 AM EST - 8 months ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Nov 7, 2025, 7:00 AM EST - 8 months ago

MiNK Therapeutics Registration statement: Registration Filing

2025-09-29T11:45:50.000Z - 10 months ago

MiNK Therapeutics appoints John Holcomb to board of directors

Sep 29, 2025, 7:30 AM EDT - 10 months ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 25, 2025, 7:30 AM EDT - 10 months ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

2025-09-18T11:40:33.000Z - 10 months ago

MiNK Therapeutics appoints Hammond as Head of Inflammatory, Pulmonary Diseases

Sep 18, 2025, 7:30 AM EDT - 10 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

2025-08-15T10:10:11.000Z - 11 months ago

MiNK Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

Aug 14, 2025, 8:30 AM EDT - 11 months ago

MiNK Therapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

MiNK Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 11 months ago

MiNK Therapeutics Earnings release: Q2 2025

2025-08-14T11:40:29.000Z - 11 months ago

MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year

Aug 14, 2025, 7:30 AM EDT - 11 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

2025-07-15T14:30:12.000Z - 1 year ago

H.C. Wainwright downgrades MiNK Therapeutics after 400% rally

Jul 15, 2025, 8:21 AM EDT - 1 year ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jun 10, 2025, 1:33 PM EDT - 1 year ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 1 year ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q1 2025

May 15, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Apr 30, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 1 year ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 1 year ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 1 year ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 20, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Dec 18, 2024, 9:45 AM EST - 1 year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Dec 6, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings release: Q3 2024

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 9, 2024, 7:00 AM EDT - 2 years ago

MiNK Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Sep 3, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Registration statement: Registration Filing

Aug 13, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 2 years ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q1 2024

May 14, 2024, 7:30 AM EDT - 2 years ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 2 years ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 29, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Proxy statement: Proxy Filing

Apr 8, 2024, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 2 years ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Biotechguy21 Jul. 14 at 8:34 PM

0 · Reply

Dancady1 Jul. 13 at 10:15 PM

$INKT nom num nom

0 · Reply

Biotechguy21 Jul. 13 at 7:09 PM

$AGEN $INKT remember how fast these pos companies atm a sp to death. Facts and stay tuned 🤡😂🤡😂🤡

0 · Reply

Spartrap Jul. 13 at 2:39 PM

1 · Reply

pedmac2000 Jul. 10 at 1:49 PM

1 · Reply

svertical1 Jul. 10 at 7:41 AM

1 · Reply

weichsel1 Jul. 9 at 1:51 PM

0 · Reply

Dancady1 Jul. 7 at 1:40 PM

$INKT no news for a while now…. Maybe some positive news with the patient in Ukraine being dosed a month ago

0 · Reply

OrientBeach Jul. 4 at 5:24 PM

$INKT Just to make a correction. Everglade is a solicitation agent for BARDA and NOT the name of BARDA’s ARDS program

0 · Reply

OrientBeach Jul. 3 at 4:00 PM

3 · Reply

Tigertkbc Jul. 1 at 9:02 PM

$INKT Just need a spark!

0 · Reply

Tigertkbc Jul. 1 at 5:31 PM

$INKT Hoping for Ibrx affiliation boost. We will see.

1 · Reply

Tigertkbc Jul. 1 at 12:01 PM

$INKT Car T Cell therapy on Fox News. Mink involved in this therapy and only a matter of time before people realize this.

0 · Reply

BioinvestorUSA Jun. 30 at 1:17 PM

$INKT smart person

0 · Reply

Tigertkbc Jun. 28 at 7:22 PM

$INKT Just you and I but our day will be coming and hopefully soon!

1 · Reply

Dancady1 Jun. 26 at 9:02 PM

$INKT anyone here ?

1 · Reply

Tigertkbc Jun. 17 at 1:56 PM

$INKT Read the transcript from meeting this morning. Exciting!

2 · Reply

Dancady1 Jun. 12 at 12:45 PM

$INKT come on to the moon inkt since we have not gone to zero we still have the science. Every day every week that passes by draws us closer to 1 billion -5billion market cap

1 · Reply

Ralph_Kramden_1 Jun. 10 at 6:24 PM

$INKT Added 1k

0 · Reply

Outcomes Jun. 2 at 8:11 PM

$INKT ….Form 4s

2 · Reply

Dancady1 Jun. 2 at 6:49 PM

$INKT is it going to pop…??

0 · Reply

Spartrap Jun. 1 at 10:14 PM

$INKT it feels like this is briskly moving from the 'trading vehicle' category just worthy of a scalp or two, to the 'great investment idea' category

1 · Reply

Market Cap	55.55M
Revenue (ttm)	0.00
Net Income (ttm)	-12.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	11,700
Avg Vol	31,628
Day's Range	N/A - N/A
Shares Out	4.98M
Stochastic %K	62%
Beta	0.47
Analysts	Strong Sell
Price Target	$39.00